[go: up one dir, main page]

CN115667291A - 一种白细胞介素29突变体蛋白 - Google Patents

一种白细胞介素29突变体蛋白 Download PDF

Info

Publication number
CN115667291A
CN115667291A CN202180037021.9A CN202180037021A CN115667291A CN 115667291 A CN115667291 A CN 115667291A CN 202180037021 A CN202180037021 A CN 202180037021A CN 115667291 A CN115667291 A CN 115667291A
Authority
CN
China
Prior art keywords
protein
pharmaceutical composition
fusion protein
conjugate
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037021.9A
Other languages
English (en)
Inventor
杨柳
李岩
冯静
郭万军
潘海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciwind Biosciences Co Ltd
Original Assignee
Sciwind Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciwind Biosciences Co Ltd filed Critical Sciwind Biosciences Co Ltd
Publication of CN115667291A publication Critical patent/CN115667291A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

提供了一种白细胞介素29(IL29)突变体蛋白、包含所述突变体蛋白融合蛋白、偶联物、药物组合物、制品和试剂盒。提供的IL29突变体蛋白具有良好的活性和稳定性，可有效预防和/或治疗病毒感染性疾病、肿瘤以及其他需要调节机体免疫功能的疾病。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN202180037021.9A 2020-05-27 2021-02-08 一种白细胞介素29突变体蛋白 Pending CN115667291A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020092613 2020-05-27
CNPCT/CN2020/092613 2020-05-27
PCT/CN2021/075907 WO2021238302A1 (zh) 2020-05-27 2021-02-08 一种白细胞介素29突变体蛋白

Publications (1)

Publication Number Publication Date
CN115667291A true CN115667291A (zh) 2023-01-31

Family

ID=78745522

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037021.9A Pending CN115667291A (zh) 2020-05-27 2021-02-08 一种白细胞介素29突变体蛋白

Country Status (6)

Country Link
US (1) US20230265144A1 (zh)
EP (1) EP4159748A4 (zh)
JP (1) JP2023527048A (zh)
CN (1) CN115667291A (zh)
AU (1) AU2021280623B9 (zh)
WO (1) WO2021238302A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085658A (zh) * 2014-05-14 2015-11-25 北京凯因科技股份有限公司 一种白细胞介素29突变体及聚乙二醇衍生物
CN107698682A (zh) * 2010-05-03 2018-02-16 百时美施贵宝公司 血清白蛋白结合分子
CN109293782A (zh) * 2014-01-08 2019-02-01 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法
CN112694526A (zh) * 2020-05-27 2021-04-23 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
CN112870336A (zh) * 2021-02-24 2021-06-01 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103923209B (zh) * 2014-05-13 2016-06-22 北京凯因科技股份有限公司 一种Lambda干扰素突变体及聚乙二醇衍生物
CN105085657A (zh) * 2014-05-14 2015-11-25 北京凯因科技股份有限公司 一种干扰素突变体及聚乙二醇衍生物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107698682A (zh) * 2010-05-03 2018-02-16 百时美施贵宝公司 血清白蛋白结合分子
CN109293782A (zh) * 2014-01-08 2019-02-01 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法
CN105085658A (zh) * 2014-05-14 2015-11-25 北京凯因科技股份有限公司 一种白细胞介素29突变体及聚乙二醇衍生物
CN112694526A (zh) * 2020-05-27 2021-04-23 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
CN113150107A (zh) * 2020-05-27 2021-07-23 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
CN112870336A (zh) * 2021-02-24 2021-06-01 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂

Also Published As

Publication number Publication date
AU2021280623B9 (en) 2024-03-14
US20230265144A1 (en) 2023-08-24
WO2021238302A1 (zh) 2021-12-02
JP2023527048A (ja) 2023-06-26
AU2021280623A1 (en) 2023-02-02
EP4159748A1 (en) 2023-04-05
EP4159748A4 (en) 2024-02-21
AU2021280623B2 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
EP2661451B1 (en) Antimicrobial fusion compounds and uses thereof
JP5396358B2 (ja) インターフェロン−β−１ａのポリマー結合体および使用
US10442845B2 (en) Interferon analogs
JP6099095B2 (ja) 組換えヒトインターフェロン様タンパク質
EA201100809A1 (ru) НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ, ВЫСОКООЧИЩЕННЫЙ, СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА АЛЬФА С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
TW202334430A (zh) 自酵母菌產生之alpha-1抗胰蛋白酶用於治療病毒感染
CN106188267B (zh) 埃兹蛋白衍生肽及其药物组合物
CN115667291A (zh) 一种白细胞介素29突变体蛋白
WO2021164576A1 (zh) 用于抗冠状病毒感染的药物及其应用
JP2013542196A5 (zh)
BRPI0621664A2 (pt) conjugado de interferon alfa com polietileno glicol
WO2021228875A1 (en) Treatment of respiratory viral infections
RU2694906C2 (ru) Пептиды производные эзрина и фармацевтические композиции на их основе
MX2013003341A (es) Formulaciones para el factor estimulante de colonia de granulocito de bovino y sus variantes.
JPWO2021238302A5 (zh)
CN102526757A (zh) 一种聚乙二醇化干扰素稳定的水溶液
NZ720748B2 (en) Ezrin-derived peptides and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 310018 Room 1802, Building 2, Hangzhou East International Business Center, Qiantang District, Hangzhou City, Zhejiang Province

Applicant after: Hangzhou Xianweida Biotechnology Co.,Ltd.

Address before: Room 815-818, building 17, No.57, kejiyuan Road, Baiyang street, Hangzhou Economic and Technological Development Zone, Hangzhou City, Zhejiang Province 310018

Applicant before: HANGZHOU SCIWIND BIOSCIENCES Co.,Ltd.

CB02 Change of applicant information
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20230131

Assignee: Zhengda Pharmaceutical (Guangzhou) Co.,Ltd.

Assignor: Hangzhou Xianweida Biotechnology Co.,Ltd.

Contract record no.: X2024980010844

Denomination of invention: A mutant protein of interleukin 29

License type: Exclusive License

Record date: 20240730

EE01 Entry into force of recordation of patent licensing contract